| Bioactivity | Navacaprant (BTRX-335140) is a selective and orally active κ opioid receptor (KOR) antagonist, has antagonist activity for κOR, μOR and δOR with IC50 values of 0.8 nM, 110 nM, and 6500 nM, respectively.Navacaprant endows with favorable in vitro ADMET and in vivo pharmacokinetic profiles and medication-like duration of action in rats. Navacaprant distributes well into the CNS and can be used for the research of neuropathy[1]. | ||||||||||||
| Invitro | Navacaprant (BTRX-335140) (0-10 μM; 4 h) shows selective antagonist activity towards Kappa Opioid Receptor[1]. Cell Viability Assay[1] Cell Line: | ||||||||||||
| In Vivo | Navacaprant (BTRX-335140) (0.01-3 mg/kg; p.o. once) reduces U69,593- stimulated plasma prolactin secretion to levels of without U69,593 treatment[1].Navacaprant (BTRX-335140) (1 mg/kg; i.p. once) blocks U-50488-induced antinociception from hot water[1].1.19Pharmacokinetic Parameters of BTRX-335140 in rodents[1]. | ||||||||||||
| Name | Navacaprant | ||||||||||||
| CAS | 2244614-14-8 | ||||||||||||
| Formula | C25H32FN5O2 | ||||||||||||
| Molar Mass | 453.55 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Guerrero M, et al. Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140). J Med Chem. 2019 Feb 28;62(4):1761-1780. |
Navacaprant
CAS: 2244614-14-8 F: C25H32FN5O2 W: 453.55
Navacaprant (BTRX-335140) is a selective and orally active κ opioid receptor (KOR) antagonist, has antagonist activity
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.